14 results about "HEART INFARCTION" patented technology

The invention discloses a myocardial infarction early warning and emergency treatment system, and belongs to the technical field of medical treatment and emergency rescue, and the system comprises a data collection module which is used for collecting various physiological parameters of a user in real time through a wearable device; the analysis module is used for receiving and analyzing the physiological parameters and calculating a myocardial infarction risk score and a prediction time window of the user; the early warning module is used for giving out graded early warning and voice self-rescue guidance according to the myocardial infarction risk score; the alarm module is used for automatically triggering an alarm process when an emergency situation is detected; the AI emergency guidance module is used for providing augmented reality visual emergency guidance for field rescuers; and the cloud platform is used for data storage, model optimization and security management. According to the invention, risk quantitative scoring and time window prediction are realized, an early warning gateway is greatly brought forward, and precious time is won for patient intervention and medical treatment.

The application belongs to the technical field of biology and specifically relates to a compound for treating myocardial infarction. The chondroitin sulfate oligosaccharide in the application is extracted from natural chondroitin sulfate, and after being treated into an oligosaccharide chain through a chemical enzyme method, experiments prove that the chondroitin sulfate oligosaccharide is helpful to the survival of myocardial cells. Compared with other similar functional products, the glycopeptide polymer hydrogel formed after the introduction of a polymer skeleton overcomes the problem of batch difference of natural products, has a clear structure, and the hydrogel itself has excellent biological activity, and does not need to encapsulate other active ingredients such as drugs. The effect of supporting the infarct area of the ventricular wall and promoting the survival of myocardial cells is obvious, the myocardial infarction area can be effectively limited, the thickness of the infarct area of the ventricular wall is increased, the damage of the heart infarction to the heart is reduced, and the application has a good application prospect.

Provided is a GLP-1 / GCG dual agonist compound. The GLP-1 / GCG dual agonist compound is used for preparing a pharmaceutical composition for treating diseases. Provided is a use of the pharmaceutical composition in the preparation of a drug for treating at least one disease of type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis, and pulmonary fibrosis.

The invention discloses a heart health monitoring method and device and a mattress, and the method comprises the steps: obtaining a heartbeat impact signal of a human body through a first type pressure sensor when determining that the human body lies on the mattress; the first type pressure sensor is arranged in the mattress; acquiring a heart rate variability index according to the heartbeat impact signal; the myocardial infarction risk condition of the human body is determined according to the heart rate variability index, so that when the user sleeps at night, the heartbeat condition can be monitored for a long time without wearing additional medical equipment, the myocardial infarction condition of the human body can be detected, sleep of the user is not affected, and the user experience is improved. And the comfort can be considered on the basis of heart monitoring.

The invention belongs to the technical field of myocardial repair hydrogel materials, and particularly relates to oxygen-producing hydrogel for myocardial repair and a preparation method of the oxygen-producing hydrogel. The preparation method comprises the following steps: carrying out a modification reaction on GelMA and KH570 in a PBS buffer solution to prepare KH570-GelMA, carrying out an oxidation reaction on cobalt chloride, strontium chloride, sodium hydroxide and sodium hypochlorite in an aqueous solution to prepare a CoOOH-Sr nanosheet, mixing the CoOOH-Sr nanosheet with the KH570-GelMA solution, introducing a photoinitiator, and carrying out in-situ curing to prepare the oxygen-producing hydrogel. Through modification of GelMA by KH570, regulation and control of crosslinking density, improvement of hydrogel porosity and introduction of CoOOH-Sr functional molecules, controllable oxygen production is realized, local hypoxia is relieved, cellular compatibility and biological activity of the hydrogel are improved, myocardial cell proliferation and tissue regeneration are promoted, and a hydrogel patch in an injection or patch form can be constructed to adapt to myocardial infarction model application.

The present invention relates to 4-oxoretinoate for use in treatment or prevention of cardiac dysfunction, heart failure, or adverse cardiac remodelling after myocardial infarction or impaired cardiac blood flow. The present invention also relates to 4-oxoretinoate for use in treatment of coronary artery disease, or of ischemia-reperfusion injury.

The invention relates to the field of biomarkers, and discloses a kit, a biomarker and a method. The invention discloses a biomarker for early prediction and / or diagnosis of heart failure after myocardial infarction. The biomarker is short-chain fatty acid. The level of short-chain fatty acid in peripheral blood of a control group and an STEMI case group is quantitatively analyzed by using a high performance liquid chromatography-tandem mass spectrometer, and it is found that the content of the short-chain fatty acid in the STEMI case group is significantly reduced compared with the control group.

Systems and methods are described for predicting the likelihood of myocardial infarction and / or accident, such as road traffic accident. Patient or user heart rate is detected and each of a plurality of heart rate n-variability (HRnV) and average heart rate n-variability (avHRnV) parameters are determined from the heart rate signal, from which a predictive model can predict the likelihood of myocardial infarction occurrence for the patient or user and, if necessary, alert the patient or user.

The invention discloses a construction method of an intermingled phlegm and blood stasis type myocardial infarction or cerebral infarction animal model, which comprises the following steps: selecting a healthy mouse, inducing an intermingled phlegm and blood stasis state by adopting a method of combining high-fat feeding with epinephrine hydrochloride subcutaneous injection, and feeding for 28 days; 1 mg / kg of epinephrine hydrochloride is subcutaneously injected every day on the 21th day, and the injection is continued for 7 days; establishing a myocardial infarction model by adopting a left coronary artery anterior descending branch ligation method, and establishing a cerebral infarction model by adopting a middle cerebral artery suture method; the invention further discloses an animal model of phlegm and blood stasis type myocardial infarction or cerebral infarction and application of the animal model to preparation of drugs for preventing or treating phlegm and blood stasis type myocardial infarction or cerebral infarction. According to the method, the phlegm-blood stasis type myocardial infarction or cerebral infarction animal model is successfully induced, the standard and objective judgment of the model state is realized by matching with an evaluation scale, the modeling method is simple, the repeatability is high, the evaluation system is scientific and reasonable, and the method has good research and application prospects.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a composition for treating atherosclerotic plaque and a preparation method thereof, and is technically characterized in that the composition is composed of the following components in parts by weight: 5-10 parts of astragalus membranaceus, 5-10 parts of gynostemma pentaphylla, 5-10 parts of roasted perillaseed, 5-10 parts of lotus leaf, 5-10 parts of seaweed, 7.5-20 parts of hawthorn, 5-10 parts of pollen typhae and 5-10 parts of rhizoma alismatis. , 5-10 parts of turmeric and 1.5-4 parts of red yeast rice. The composition disclosed by the invention is used for treating coronary heart disease angina, myocardial infarction, atherosclerotic plaque and lower limb atherosclerotic obliterans, has obvious curative effects, does not have other side effects except for loose stools after individual patients take the composition, and provides important guiding significance for treatment of atherosclerotic plaque and development of medicines.

The present invention relates to the technical field of traditional Chinese medicine compositions, and specifically discloses a composition for treating atherosclerotic plaques and a preparation method thereof. The technical key points are as follows: The composition is composed of the following components in parts by weight: 5-10 parts of Astragalus membranaceus, 5-10 parts of Gynostemma pentaphyllum, 5-10 parts of roasted Perilla seeds, 5-10 parts of lotus leaf, 5-10 parts of Sargassum, 7.5-20 parts of Hawthorn Fruit, 5-10 parts of Pollen Typhae, 5-10 parts of Alisma orientale, 5-10 parts of Curcuma longa, and 1.5-4 parts of Monascus purpureus. The composition of the present invention has obvious curative effects in the treatment of coronary heart disease angina pectoris, myocardial infarction, atherosclerotic plaques, and lower extremity atherosclerotic obliterans. Except for loose stools in some patients after taking the medicine, no other side effects have been found, which provides important guiding significance for the treatment of atherosclerotic plaques and the development of drugs.

The utility model discloses a first-aid oxygen cylinder for cardiovascular diseases, and relates to an oxygen supply device for family rescue of patients with myocardial infarction in the acute stage. Comprising an oxygen cylinder body (1), an elastic head hoop (3), an elliptical annular sliding body (4), an oxygen pipe bracket (5) and a pipe clamp (6), an annular body is fixedly sleeved on the oxygen cylinder body; the other ends of the two elastic steel sheets are overlapped to form an elastic head band with an annular structure, and the section of the overlapped position of the elastic steel sheets is of an oval structure; the elliptical ring-shaped sliding body is sleeved outside the two overlapped arc-shaped bulges, the upper end of the oxygen pipe bracket formed by the arc-shaped steel sheets is fixed with the elliptical ring-shaped sliding body, and the lower end of the oxygen pipe bracket is fixed with the pipe clamp; and the tail end of the oxygen pipe is clamped in the pipe clamp. The problems that an existing household oxygen inhalation tube oxygen supply device cannot be correctly worn on a patient in time, and an existing oxygen supply device used in a small family supplies oxygen to the patient through a mask, so that the oxygen supply concentration is too high, and the negative effect on myocardial infarction acute stage rescue is achieved are solved.

We provide herein a method of preventing or limiting the effects of heart failure in a human patient with persistent myocardial infarction by reducing poorly adapted cardiac remodeling in the patient. The method includes percutaneously inserting a transcatheter blood pump comprising a trochanter and a cannula into the vasculature of the patient and positioning the cannula across the aortic valve of the heart of the patient with the distal end of the cannula located in the left ventricle of the heart and the proximal end of the pump located in the aorta. The method then includes operating the positioned pump to unload the left ventricle at a blood flow pumping rate of at least 2.5 L / min for a support period of between at least 30 minutes and less than 60 minutes prior to reperfusion of the heart. Then, after the support period, the method includes applying coronary reperfusion therapy to the heart.

The application relates to the field of biological medicine, and discloses application of stanniocalcin 2 in preparation of myocardial infarction treatment drugs. It is found for the first time that overexpression of stanniocalcin 2 can promote survival and proliferation of myocardial cells after heart infarction, and it is further found that STC2 drives survival and proliferation of myocardial cells after heart infarction by combining with PURA. Therefore, a new treatment target for heart repair after heart infarction is expected to be provided.